Trials / Withdrawn
WithdrawnNCT03062176
Interleukin-1 Blockade for the Treatment of Heart Failure in Patients With Advanced Chronic Kidney Disease
Interleukin-1 Blockade for the Treatment of Heart Failure in Patients With Advanced Chronic Kidney Disease (E-HART)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Virginia Commonwealth University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Interleukin-1 blockade for the treatment of heart failure in patients with advanced chronic kidney disease (End-stage renal disease and Heart fAilure - Anakinra Remodeling Trial) is a Phase 2, single-arm trial designed to estimate the effect of anakinra, a recombinant human Interleukin-1 (IL-1) receptor antagonist, on cardiorespiratory fitness in patients with advanced chronic kidney disease and heart failure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anakinra | Anakinra (Kineret) |
Timeline
- Start date
- 2017-04-03
- Primary completion
- 2019-05-15
- Completion
- 2019-05-15
- First posted
- 2017-02-23
- Last updated
- 2019-05-17
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03062176. Inclusion in this directory is not an endorsement.